IRX-616a

NX1 shares surge 35% as Nexalis Therapeutics sets out 2026 clinical roadmap

Finance

NX1 shares surge 35% as Nexalis Therapeutics sets out 2026 clinical roadmap

February 17, 2026

Company Roundup: Avecho, InhaleRx, Neurotech, Peak, Zelira, Argent

Finance

Company Roundup: Avecho, InhaleRx, Neurotech, Peak, Zelira, Argent

February 02, 2026

Elixinol Achieves Operating Cash Flow Positive Quarter for the First Time

Finance

Elixinol Achieves Operating Cash Flow Positive Quarter for the First Time

February 02, 2026

Finance

InhaleRx closes A$1m capital raise and prepares to become Nexalis Therapeutics

December 01, 2025

Financial Roundup: Elixinol and Avecho Post Wider Losses; InhaleRx Gets Ethics Approval; Zelira Trims Deficit; Argent Steps Back From Non-Core Work

Medical

Financial Roundup: Elixinol and Avecho Post Wider Losses; InhaleRx Gets Ethics Approval; Zelira Trims Deficit; Argent Steps Back From Non-Core Work

August 29, 2025

InhaleRx posts wider half-year loss as clinical trial programs gain momentum

Finance

InhaleRx posts wider half-year loss as clinical trial programs gain momentum

August 26, 2025

InhaleRx moves closer to patient dosing in cancer pain and panic disorder programs

Medical

InhaleRx moves closer to patient dosing in cancer pain and panic disorder programs

July 23, 2025

Round-Up: Tilray enters pastille market; InhaleRx advances panic disorder study; NSW hemp plan open for comment; BS3 names new general manager

Hemp

Round-Up: Tilray enters pastille market; InhaleRx advances panic disorder study; NSW hemp plan open for comment; BS3 names new general manager

April 23, 2025